AMYLYX PHARMACEUTICALS INC (AMLX)
Health Care · Rare disease biopharmaceuticals · NASDAQ
A clinical-stage pharmaceutical company developing first-in-class GLP-1 antagonist avexitide to treat post-bariatric hypoglycemia and other rare metabolic disorders.
What AMYLYX PHARMACEUTICALS INC does
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for rare endocrine conditions and neurodegenerative diseases with high unmet medical needs. The company is advancing a pipeline of investigational therapies across multiple disease areas, with its lead candidate being avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism. The company is also developing AMX0035 for Wolfram syndrome, AMX0114 for ALS, and AMX0318 for rare metabolic disorders.
Themes: ["GLP-1 / metabolic disorders","post-bariatric hypoglycemia (PBH)","rare endocrine diseases","neurodegenerative diseases","congenital hyperinsulinism"]
Fundamentals
- Price$18.38 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+156.2% as of 2026-07-09 close
- Net margin-94.6% as of 2026-07-10
- Gross margin+82.8% as of 2026-07-10
- ROE-55.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.20 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial failure risk: LUCIDITY Phase 3 trial for avexitide in PBH enrolled only 78 participants and results expected Q3 2026; failure to meet primary endpoints or approval would be catastrophic for the company","Regulatory approval uncertainty: avexitide is a first-in-class GLP-1 antagonist with no comparable approved therapies, making FDA approval precedent-dependent and unpredictable","Severe cash burn: unprofitable with -94.56% net margin and clinical-stage pipeline generates no revenue, requiring continued fundraising to support development activities"]
Competitors & peers
- Eli Lilly (LLY) - GLP-1 receptor agonist portfolio
- Novo Nordisk (NVO) - GLP-1 receptor agonist portfolio
- Viking Therapeutics - GLP-1 receptor agonist development
- Rhythm Biosciences - rare disease therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.